Dysregulation of glutaminase and glutamine synthetase in cancer. (28th December 2019)

• Record Type: Journal Article
• Authors: Matés, José M.; Campos-Sandoval, José A.; Santos-Jiménez, Juan de los; Márquez, Javier
• Is Part Of: Cancer letters. Volume 467(2019)
• Page Start: 29
• Page End: 39
• Publication Date: 2019-12-28
• Subjects: Cancer metabolism -- Combination therapy -- Glutaminase isoenzymes -- Glutamine -- Glutamine synthetase -- Synergistic inhibitors; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2019.09.011
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Besides fast glucose catabolism, many types of cancers are characterized by elevated glutamine consumption. Medical oncology pursuits to block specific pathways, mainly glycolysis and glutaminolysis, in tumor cells to arrest cancer development. This strategy frequently induces adaptive metabolic resistance that must be countered. Combination therapy is an anticancer synergistic tool to overcome both cancer growth and resistance mechanisms. Dysregulation of glutaminase and glutamine synthetase are key events that allow anabolic adaptation of tumors. Several specific drugs that inhibit metabolic enzymes dealing with glutamine metabolism have been able to eliminate some neoplasms. Targeting the tumor microenvironment can be also another essential factor to be taken into account when single or combined cancer metabolic therapy fails. Highlights: Dysregulation of glutaminases is a hallmark in many types of cancer. Glutaminases and glutamine synthetase are therapeutic targets for cancer. To overcome drug resistance multiple metabolic inhibition is usually required. Targeting tumor microenvironment must be considered in metabolic therapy.